Toujeo is the next generation, longer-acting version of Lantus (insulin glargine) which is facing growing competition from rivals and biosimilar versions. Lantus is the world's biggest selling ...

The marketing authorisation for the Alliance's insulin glargine product is based upon a comprehensive clinical data programme, which showed it has similar efficacy and safety compared to Lantus in ...

Objective—Insulin glargine (Lantus) is an extended-action insulin analog with greater stability and duration of action than regular human insulin. The long duration of action and decreased ...

One group received two oral drugs (metformin plus the sulfonylurea glimepiride [Amaryl]) plus morning doses of glargine insulin (Lantus); the other group received twice-daily premixed insulin (70% ...

The interchangeable Semglee product, which will allow substitution of Semglee for the reference product, Lantus(R), at the ... a quality Biosimilar Insulin Glargine.” Biocon Biologics Managing ...